Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis

Gavaldà, J.; Martín, M.ía.-T.; López, P.; Gomis, X.; Ramírez, J.é-L.ís.; Rodríguez, D.; Len, O.; Puigfel, Y.; Ruíz, I.; Pahissa, A.

Antimicrobial Agents and ChemoTherapy 49(7): 3028-3030

2005


ISSN/ISBN: 0066-4804
PMID: 15980392
DOI: 10.1128/aac.49.7.3028-3030.2005
Accession: 004140226

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
The efficacy of therapeutic aerosolized amphotericin B (AMB) was studied in a steroid-immunosuppressed murine model of invasive pulmonary aspergillosis. Nebulized liposomal AMB can be a valid approach to the treatment of this infection, with subjects showing significantly improved survival relative to that of subjects given intravenous deoxycholate AMB, as well as lower lung weights and pulmonary glucosamine levels.